Go to Liminal BioSciences Q1 2021 Results Conference Call on Tuesday May 18, 2021 8:30 AM EST
View NowOther content in this Stream
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility
Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion
Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)
